[Application of defibrotide in hepatic sinusoidal obstruction syndrome induced by hematopoietic stem cell transplantation].
Zhonghua Gan Zang Bing Za Zhi
; 29(1): 92-96, 2021 Jan 20.
Article
em Zh
| MEDLINE
| ID: mdl-33541030
ABSTRACT
Hepatic sinusoidal obstruction syndrome (HSOS) is the most common early complication in patients with hematopoietic stem cell transplantation (HSCT). According to reports, the average incidence of HSOS post-HSCT is 13.7% (0~62%). HSOS may be accompanied by multiple organ failure, and the mortality rate can exceed 80% at 100 days of onset. Defibrotide is currently the safest and most effective drug used to prevent and treat HSOS post-HSCT. It is currently the only drug approved in the United States for the treatment of HSOS with lung/renal dysfunction post-HSCT. In addition, it has been approved in the European Union for the treatment of severe HSOS cases post-HSCT. This article briefly describes and summarizes the research progress, clinical application, pharmacokinetics, efficacy, safety, dose and treatment of defibrotide in HSOS post-HSCT.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Hepatopatia Veno-Oclusiva
/
Transplante de Células-Tronco Hematopoéticas
Tipo de estudo:
Etiology_studies
Limite:
Humans
País/Região como assunto:
America do norte
Idioma:
Zh
Ano de publicação:
2021
Tipo de documento:
Article